FR2718749B1 - Vecteurs viraux et utilisation en thérapie génique. - Google Patents

Vecteurs viraux et utilisation en thérapie génique.

Info

Publication number
FR2718749B1
FR2718749B1 FR9404590A FR9404590A FR2718749B1 FR 2718749 B1 FR2718749 B1 FR 2718749B1 FR 9404590 A FR9404590 A FR 9404590A FR 9404590 A FR9404590 A FR 9404590A FR 2718749 B1 FR2718749 B1 FR 2718749B1
Authority
FR
France
Prior art keywords
gene therapy
viral vectors
viral
vectors
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9404590A
Other languages
English (en)
Other versions
FR2718749A1 (fr
Inventor
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9404590A priority Critical patent/FR2718749B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Gustave Roussy (IGR) filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU72646/94A priority patent/AU7264694A/en
Priority to DE69435108T priority patent/DE69435108D1/de
Priority to ES94922889T priority patent/ES2310924T3/es
Priority to HU9500732A priority patent/HU216871B/hu
Priority to JP50436895A priority patent/JP4190028B2/ja
Priority to BR9405507A priority patent/BR9405507A/pt
Priority to CA002144040A priority patent/CA2144040A1/fr
Priority to KR1019950700975A priority patent/KR100356615B1/ko
Priority to NZ269156A priority patent/NZ269156A/en
Priority to SK312-95A priority patent/SK282843B6/sk
Priority to DK94922889T priority patent/DK0667912T3/da
Priority to CN94190594A priority patent/CN1115414C/zh
Priority to AT94922889T priority patent/ATE399873T1/de
Priority to RU95108217/13A priority patent/RU2219241C2/ru
Priority to PT94922889T priority patent/PT667912E/pt
Priority to CZ1995639A priority patent/CZ287157B6/cs
Priority to PL94308122A priority patent/PL179877B1/pl
Priority to PCT/FR1994/000851 priority patent/WO1995002697A1/fr
Priority to EP94922889A priority patent/EP0667912B1/fr
Priority to IL11028494A priority patent/IL110284A0/xx
Priority to NO19950939A priority patent/NO321309B1/no
Priority to FI951138A priority patent/FI951138A/fi
Publication of FR2718749A1 publication Critical patent/FR2718749A1/fr
Publication of FR2718749B1 publication Critical patent/FR2718749B1/fr
Application granted granted Critical
Priority to US10/301,085 priority patent/US20030096787A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
FR9404590A 1993-07-13 1994-04-18 Vecteurs viraux et utilisation en thérapie génique. Expired - Fee Related FR2718749B1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR9404590A FR2718749B1 (fr) 1994-04-18 1994-04-18 Vecteurs viraux et utilisation en thérapie génique.
RU95108217/13A RU2219241C2 (ru) 1993-07-13 1994-07-08 Дефектный рекомбинантный аденовирусный вектор (варианты)
ES94922889T ES2310924T3 (es) 1993-07-13 1994-07-08 Vectores adenovirales defectivos y utilizacion en terapia genica.
HU9500732A HU216871B (hu) 1993-07-13 1994-07-08 Defektív adenovírusvektorok és génterápiai alkalmazásuk
JP50436895A JP4190028B2 (ja) 1993-07-13 1994-07-08 欠陥組換えアデノウイルスベクター及び遺伝子治療での使用
BR9405507A BR9405507A (pt) 1993-07-13 1994-07-08 Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
CA002144040A CA2144040A1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique
KR1019950700975A KR100356615B1 (ko) 1993-07-13 1994-07-08 결함아데노바이러스벡터및유전자치료에서그의사용
NZ269156A NZ269156A (en) 1993-07-13 1994-07-08 Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
SK312-95A SK282843B6 (sk) 1993-07-13 1994-07-08 Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
DK94922889T DK0667912T3 (da) 1993-07-13 1994-07-08 Defekte adenovirusvektorer og anvendelse heraf i genterapi
CN94190594A CN1115414C (zh) 1993-07-13 1994-07-08 用于基因治疗的病毒载体
AU72646/94A AU7264694A (en) 1993-07-13 1994-07-08 Defective adenovirus vectors and use thereof in gene therapy
AT94922889T ATE399873T1 (de) 1993-07-13 1994-07-08 Defekte adenovirus-vektoren und deren verwendung in der gentherapie
EP94922889A EP0667912B1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique
CZ1995639A CZ287157B6 (en) 1993-07-13 1994-07-08 Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
PL94308122A PL179877B1 (pl) 1993-07-13 1994-07-08 Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL
PCT/FR1994/000851 WO1995002697A1 (fr) 1993-07-13 1994-07-08 Vecteurs adenoviraux defectifs et utilisation en therapie genique
PT94922889T PT667912E (pt) 1993-07-13 1994-07-08 Vectores adenovirais deficientes e utilização em terapia génica
DE69435108T DE69435108D1 (de) 1993-07-13 1994-07-08 Defekte adenovirus-vektoren und deren verwendung in der gentherapie
IL11028494A IL110284A0 (en) 1993-07-13 1994-07-11 Viral vectors and their use in gene therapy
NO19950939A NO321309B1 (no) 1993-07-13 1995-03-10 Defektive, rekombinante adenovirus, cellelinje, samt et farmasoytisk preparat.
FI951138A FI951138A (fi) 1993-07-13 1995-03-10 Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
US10/301,085 US20030096787A1 (en) 1993-07-13 2002-11-21 Defective adenovirus vectors and use thereof in gene therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9404590A FR2718749B1 (fr) 1994-04-18 1994-04-18 Vecteurs viraux et utilisation en thérapie génique.

Publications (2)

Publication Number Publication Date
FR2718749A1 FR2718749A1 (fr) 1995-10-20
FR2718749B1 true FR2718749B1 (fr) 1996-05-31

Family

ID=9462206

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9404590A Expired - Fee Related FR2718749B1 (fr) 1993-07-13 1994-04-18 Vecteurs viraux et utilisation en thérapie génique.

Country Status (1)

Country Link
FR (1) FR2718749B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
JPH08503855A (ja) * 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療

Also Published As

Publication number Publication date
FR2718749A1 (fr) 1995-10-20

Similar Documents

Publication Publication Date Title
FR2725726B1 (fr) Vecteurs viraux et utilisation en therapie genique
FR2707664B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
IL111681A0 (en) Recombinant viruses and their use in gene therapy
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
NO943344L (no) MN-gen og -protein
DK0941056T3 (da) Sphingomyelinasepræparater samt anvendelse deraf
FR2718150B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
IT1291135B1 (it) Vettori ricombinanti utilizzabili in terapia genica
IL111682A0 (en) Recombinant viruses and their use in gene therapy
FI923911A0 (fi) Dna-molekylers in vitro-syntes.
NO974179D0 (no) Rekombinante viruser som uttrykker lecitin-kolesterol-acyltransferase, og anvendelse derav i genterapi
IS2207B (is) Karbósýklískt kirnisleifar hemisúlfat og notkun þess við meðhöndlun á veirusýkingum
NO963487D0 (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
FR2725213B1 (fr) Vecteurs viraux et utilisation en therapie genique
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2718749B1 (fr) Vecteurs viraux et utilisation en thérapie génique.
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
KR960010685A (ko) 펩티드 및 그 용도
FR2766049B1 (fr) Cyclotron compact et son utilisation en proton-therapie
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
NO971359D0 (no) Humant galaktokinase-gen
AU3698699A (en) Vectors and viruses used in gene therapy
IL112994A0 (en) Recombinant viruses, their preparation and their use in gene therapy
HUP0101911A3 (en) Novel sequence class of genes, corresponding proteins and the use of the same
GB9501978D0 (en) Nucleic acids, proteins and their use in therapy

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20091231